Diagnosis, treatment, and prevention of venous thromboembolism in pregnancy

Postgraduate Medicine

Volumn 126, Issue 7, 2014, Pages 25-34

  Marshall, Ariela L ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Anticoagulation; Pregnancy; Thrombosis; Venous thromboembolism

Indexed keywords

ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD VESSEL INJURY; BREAST FEEDING; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; EMBRYOPATHY; HUMAN; HYPOPLASIA; LUNG EMBOLISM; META ANALYSIS (TOPIC); PREECLAMPSIA; PREGNANCY; PROTEINURIA; PUERPERIUM; RADIATION DOSE; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOPLASTIN TIME; VENOUS THROMBOEMBOLISM; FEMALE; GENETICS; POSTNATAL CARE; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PULMONARY EMBOLISM;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BREAST FEEDING; FEMALE; HEPARIN; HUMANS; POSTNATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PULMONARY EMBOLISM; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 84925226372     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.11.2830     Document Type: Article

References (79)

1. Anderson BS, Steffensen FH, Sorensen HT, et al. The cumulative incidence of venous thromboembolism during pregnancy and puerperium— an 11 year Danish population-based study of 63,000 pregnancies. Acta Obstet Gynecol Scand. 198;77(2):170–173.
2. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697–706.
3. Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med. 2008;359(19):2025–2033.
4. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4):632–637.
5. Kamel H, Navi BB, Sriram N, et al. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med. 2014;370(14): 1307–1315.
6. Gherman RB, Goodwin TM, Leung B, et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol. 1999;94(5 Pt 1):730–734.
7. Centre for Maternal and Child Enquiries (CMACE). Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–08. The eighth report on confidential enquiries into maternal deaths in the United Kingdom. BJOG. 2011;118(Suppl 1):1–203.
8. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancyrelated mortality in the United States, 1998 to 2005. Obstet Gynecol. 2010;116(6):1302–1309.
9. Rodger MA, Walker M, Wells PS. Diagnosis and treatment of venous thromboembolism in pregnancy. Best Pract Res Clin Haematol. 2003;16(2):279–296.
10. Hague WM, Dekker GA. Risk factors for thrombosis in pregnancy. Best Pract Res Clin Haematol. 2003;16(2):197–210.
11. Gibson PS, Powrie R. Anticoagulants and pregnancy: when are they safe? Cleve Clin J Med. 2009;76(2):113–127.
12. James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol. 2005;193(1):216–219.
13. Chan WS, Spencer FA, Ginsberg JS. Anatomic distribution of deep vein thrombosis in pregnancy. CMAJ. 2010;182(7):657–660.
14. Greer IA. Prevention of venous thromboembolism in pregnancy. Best Pract Res Clin Haematol. 2003;16(2):261–278.
15. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342(6):374–380.
16. American College of Obstetricians and Gynecologists Women’s Health Care Physicians. ACOG Practice bulletin no. 138: Inherited thrombophilias in pregnancy. Obstet Gynecol. 2013;122(3):706–717.
17. Kujovich JL, Alving BM. Management of thrombophilia and antiphospholipid syndrome during pregnancy. In: Kitchens CS, Alving BM, Kessler Craig M, eds. Consultative Hemostasis and Thrombosis, 2nd ed. Philadelphia: Elsevier; 2007:593–609.
18. Greer IA. Thrombosis in pregnancy: updates in diagnosis and management. Hematology Am Soc Hematol Educ Program. 2012;2012: 203–207.
19. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5): 1311–1315.
20. Jacobsen AF, Skjeldestat FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium— a register-based case control study. Am J Obstet Gynecol. 2008; 198(2):233–234.
21. Sultan AA, Tata LJ, West J, et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood. 2013;121(19):3953–3961.
22. Refuerzo JS, Hechtman JL, Redman ME, Whitty JE. Venous thromboembolism during pregnancy. Clinical suspicion warrants evaluation. J Reprod Med. 2003;48(10):767–770.
23. Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med. 1998;128(8):663–677.
24. Fraser DG, Moody AR, Morgan PS, et al. Diagnosis of lower-limb deep venous thrombosis: a prospective blinded study of magnetic resonance direct thrombus imaging. Ann Intern Med. 2002;136(2):89–98.
25. Chan WS, Spencer FA, Lee AY, et al. Safety of withholding anticoagulation in pregnant women with suspected deep vein thrombosis following negative serial compression ultrasound and iliac vein imaging. CMAJ. 2013;185(4):E194–E200.
26. Revel MP, Cohen S, Sanchez O, et al. Pulmonary embolism during pregnancy: diagnosis with lung scintigraphy or CT angiography? Radiology. 2011;258(2):590–598.
27. Cahill AG, Stout MJ, Macones GA, Bhalla S. Diagnosing pulmonary embolism in pregnancy using computed-tomographic angiography or ventilation-perfusion. Obstet Gynecol. 2009;114(1):124–129.
28. Winer-Muram HT, Boone JM, Brown HL, et al. Pulmonary embolism in pregnant patients: fetal radiation dose with helical CT. Radiology. 2002;224(2):487–492.
29. Centers for Disease Control and Prevention. Radiation and pregnancy: a fact sheet for clinicians. www.bt.cdc.gov/radiation/prenatalphysician. asp. Accessed August 20, 2014.
30. Bourjelly G, Chalhoub M, Phornphutkul C, et al. Neonatal thyroid function: effect of a single exposure to iodinated contrast medium in utero. Radiology. 2010;256(3):744–750.
31. Leung AN, Bull TM, Jaeschke R, et al. An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy. Am J Respir Crit Care Med. 2011;184(10):1200–1208.
32. Chan WS, Chunilal S, Lee A, et al. A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med. 2007;147(3):165–170.
33. To MS, Hunt BJ, Nelson-Piercy C. A negative D-dimer does not exclude venous thromboembolism (VTE) in pregnancy. J Obstet Gynaecol. 2008;28(2):222–223.
34. Chan WS, Lee A, Spencer FA, et al. Predicting deep venous thrombosis in pregnancy: out in “LEFt” field? Ann Intern Med. 2009;151(2):85–92.
35. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular- weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl):64S–94S.
36. Cosmi B, Palareti G. Old and new heparins. Thromb Res. 2012;129(3): 388–391.
37. Van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004;4:CD001100.
38. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401–407.
39. Romualdi E, Dentali F, Rancan E, et al. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a metaanalysis of the literature. J Thromb Haemost. 2013;11(2):270–281.
40. Battinelli EM, Marshall A, Connors JM. The role of thrombophilia in pregnancy. Thrombosis. 2013;2013:516420.
41. Bates SM, Greer IA, Middeldorp S, et al. VTE, Thrombophilia, antithrombotic therapy, and pregnancy. Chest. 2012;141(2 Suppl): e691S–736S.
42. Voke J, Keidan J, Pavord S, et al. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol. 2007;139(4):545–558.
43. Knight M; UK Obstetric Surveillance System. Antenatal pulmonary embolism: risk factors, management and outcomes. BJOG. 2008;115(4):453–461.
44. Rodie VA, Thomson AJ, Stewart FM, et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. BJOG. 2002;109(9):1020–1024.
45. Young SK, Al-Mondhiry HA, Vaida SJ, et al. Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature. Pharmacotherapy. 2008;28(12): 1531–1536.
46. Ekbatani A, Asaro LR, Malinow AM. Anticoagulation with argatroban in a parturient with heparin-induced thrombocytopenia. Int J Obstet Anesth. 2010;19(1):82–87.
47. Ciurzynski M, Jankowski K, Pietrzak B, et al. Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia. Med Sci Monit. 2011;17(5):CS56–CS59.
48. Holst J, Lindblad B, Berggvist D, et al. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers. Blood Coagul Fibrinolysis. 1994;5(5):795–803.
49. Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost. 2002;87(5):831–835.
50. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med. 2004;350(18):1914–1915.
51. Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Annu Rev Pharmacol Toxicol. 2012;52:79–99.
52. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980;68(1):122–140.
53. Schaefer C, Hannemann D, Meister R, et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost. 2006;95(6):959–957.
54. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000;160(2):191–196.
55. Salazar E, Zajarias A, Gutierrez N, Iturbe I. The problem of cardiac valve prostheses, anticoagulants, and pregnancy. Circulation. 1984;70(3 Pt 2):169–177.
56. Iturbe-Alessio I, Fonseca MC, Mutchinik O, et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med. 1986;315(22):1390–1393.
57. Wesseling J, Van Driel D, Heymans HS, et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost. 2001;85(4):609–613.
58. Lee HC, Cho SY, Lee HJ, et al. Warfarin-associated fetal intracranial hemorrhage: a case report. J Korean Med Sci. 2003;18(5):764–767.
59. Pati S, Helmbrecht GD. Congenital schizencephaly associated with in utero warfarin exposure. Reprod Toxicol. 1994;8(2):115–120.
60. Bapat P, Kedar R, Lubetsky A, et al. Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol. 2014;123(6):1256–1261.
61. Anderson DR, Ginsberg GS, Burrows R, Brill-Edwards P. Subcutaneous heparin therapy during pregnancy: a need for concern at the time of delivery. Thromb Haemost. 1991;65(3):248–250.
62. Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence- Based Guidelines (3rd edition). Reg Anesth Pain Med. 2010;35(1): 64–101.
63. Middeldorp S. How I treat pregnancy-related venous thromboembolism. Blood. 2011;118(20):5394–5400.
64. Richter C, Sitzman J, Lang P, et al. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol. 2001;52(6):708–710.
65. GlaxoSmithKline. Product monograph: Arixtra. 2013. http://www.gsk. ca/english/docs-pdf/product-monographs/Arixtra.pdf. Accessed August 5, 2014.
66. Holden EL, Ranu H, Sheth A, et al. Thrombolysis for massive pulmonary embolism in pregnancy—a report of three cases and follow up over a two year period. Thromb Res. 2011;127(1):58–59.
67. Te Raa GD, Ribbert LS, Snijder RJ, Biesma DH. Treatment options in massive pulmonary embolism during pregnancy: a case report and review of literature. Thromb Res. 2009;124(1):1–5.
68. Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14(2):131–136.
69. Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80(4):614–620.
70. Galli M, Barbui T. Antiphospholipid antibodies in pregnancy. Best Pract Res Clin Haematol. 2003;16(2):211–225.
71. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002;195(2):211–220.
72. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314(7076):253–257.
73. Franklin RD, Kutteh WH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APAP positive population. Hum Reprod. 2002;17(11):2981–2985.
74. Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med Sci Monit. 2006;12(3):CR132–CR136.
75. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174(5):1584–1589.
76. Mak A, Cheung MW, Cheak AA, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology. 2010;49(2):281–288.
77. Stephenson MD, Ballem PJ, Tsang P, et al. Treatment of antiphospholipid antibody síndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can. 2004;26(8):729–734.
78. Noble LS, Kutteh WH, Lashey N, et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril. 2005;83(3):684–690.
79. Fouda UM, Saved AM, Abdou AM, et al. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int J Gynaecol Obstet. 2011;112(3):211–215.